GERN - NASDAQ

Geron Corporation

GERN·NASDAQ

$1.16

-0.85%

HealthcareBiotechnology

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$744.16M

EPS-0.1300

P/E Ratio-8.92

Earnings Date08/05/2026

gern

Research Development Expenses

Last Annual Value

73.72M

3-Year CAGR

-8%

5-Year CAGR

10-Year CAGR

15%

Adjust for Inflation

Geron Corporation Competitors Analysis of research-development-expenses

GERN · NASDAQ

Company	research-development-expenses	CAGR 3Y	CAGR 5Y	CAGR 10Y
Geron Corporation NASDAQ:GERN	73.72M	-16.2%	-3.0%	15.1%
Tyra Biosciences, Inc. NASDAQ:TYRA	102.93M	18.1%	37.9%	N/A
Vir Biotechnology, Inc. NASDAQ:VIR	432.80M	-9.3%	-0.7%	N/A
Arvinas, Inc. NASDAQ:ARVN	282.90M	-9.3%	9.4%	30.4%
Rezolute, Inc. NASDAQ:RZLT	61.53M	12.0%	32.6%	20.6%
Day One Biopharmaceuticals, Inc. NASDAQ:DAWN	148.13M	4.3%	27.7%	N/A
Savara Inc. NASDAQ:SVRA	81.40M	22.5%	22.9%	25.8%
Replimune Group, Inc. NASDAQ:REPL	189.45M	14.4%	26.9%	N/A
LENZ Therapeutics, Inc. NASDAQ:LENZ	18.67M	-32.0%	-13.2%	N/A
ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP	153.35M	33.2%	88.6%	N/A

Geron Corporation Fair Value Envelope

GERN · NASDAQ

Our analysis suggests that GERN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.16, this represents a potential HIDDEN relative to our calculated worth for Geron Corporation.

HIDDEN

Intrinsic Value

Current Price: $1.16

Related Guides

Blog Categories

Continue your GERN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.